TapImmune (NASDAQ:MRKR) announced its quarterly earnings data on Tuesday. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.12, Bloomberg Earnings reports.
NASDAQ MRKR traded down $0.19 during trading hours on Wednesday, reaching $6.63. The company had a trading volume of 28,146 shares, compared to its average volume of 244,626. TapImmune has a 1-year low of $2.58 and a 1-year high of $13.55. The stock has a market capitalization of $314.58 million, a P/E ratio of -5.72 and a beta of -0.32.
Separately, Piper Jaffray Companies assumed coverage on shares of TapImmune in a research report on Monday, October 22nd. They issued a “neutral” rating on the stock.
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
See Also: Dollar Cost Averaging
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.